Participants ( plasma HIV-RNA > @ log@ copies per mL , CD@ T-cell count @-@ cells per L ) were randomly assigned by a computer-generated sequence with a blocking factor of four ( stratified by clinical site and by screening viral load ) to receive tenofovir plus emtricitabine with either a reduced daily dose ( @ mg ) or a standard dose ( @ mg ) of efavirenz .